therap: cabazitaxel versus 177lu-psma-617 for mcrpc
Published 3 years ago • 263 plays • Length 2:37Download video MP4
Download video MP3
Similar videos
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
4:06
dr deepak dabkara | 177lu-psma-617 (lupsma) versus cabazitaxel in mcrpc progressing after docetaxel
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
4:00
therap trial and effectiveness of lu-psma-617
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
5:37
177lu-psma-617 for the early treatment of prostate cancer